Ask about this productRelated genes to: SLC22A16 Blocking Peptide
- Gene:
- SLC22A16 NIH gene
- Name:
- solute carrier family 22 member 16
- Previous symbol:
- -
- Synonyms:
- FLIPT2, CT2, OKB1, OAT6
- Chromosome:
- 6q21
- Locus Type:
- gene with protein product
- Date approved:
- 2003-10-08
- Date modifiied:
- 2016-02-18
Related products to: SLC22A16 Blocking Peptide
Related articles to: SLC22A16 Blocking Peptide
- Histamine has various associations with gastric cancer (GC); however, the mechanisms underlying histamine functions in GC have not been established. This study aimed to examine histamine-linked prognostic genes and mechanisms in GC. Relevant data were sourced from public databases, and differential expression, multivariate Cox, univariate Cox, and machine learning regression analyses were performed to identify prognostic genes associated with histamine in GC. Subsequently, a prognostic model was constructed. Independent prognostic factors linked to GC prognosis were determined through regression analyses and used for nomogram model construction. Furthermore, Gene Set Enrichment Analysis (GSEA) and drug sensitivity and immune infiltration analyses were conducted to explore the potential function of these genes in GC from various perspectives. Finally, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to validate the expression of GRP, NPPB, SERPINE1, GAMT, MMRN1, and SLC22A16 in GC and paracarcinoma tissue. - Source: PubMed
Publication date: 2026/03/11
Zhang YanLiu NaDong XiaoLi YuGeng JinruiLi Yonghong - Histone lactylation is an emerging epigenetic modification involved in tumor progression, but its transcriptional characteristics and clinical relevance in prostate cancer (PCa) remain poorly understood. - Source: PubMed
Publication date: 2026/02/24
Yan YunkunLi ZhuoYe MushiLi Jianchang - There are currently no effective pharmacological treatments for Sjögren's disease (SjD). Our study aims to identify potential therapeutic targets for the condition using druggable genome-wide Mendelian randomization (MR). - Source: PubMed
Publication date: 2025/11/27
He JialeLi KesongGuo ZilinZhou XinyaoTang Xiaopo - Blood metabolomes have been linked to osteoporosis, yet the precise causal relationship with osteopenia, its preventable early stage, remains unclear. This study aimed to uncover the genetic causality between blood metabolomes and osteopenia, pinpointing potential targets for mechanomedicine. Utilizing genome-wide association study summary statistics, we analyzed 1091 metabolites and 309 metabolite ratios from 8299 individuals, correlating them with total body bone mineral density (BMD) from 56,284 individuals in the IEU GWAS database and osteopenia data from 408,961 European populations. Through two-sample Mendelian randomization, we investigated the association between blood metabolomes and skeletal characteristics. We then conducted summary-data-based Mendelian randomization (MR) analysis and colocalization analyses to identify causal genes related to skeletal phenotypes, predicting therapeutic targets for osteopenia. Expression of potential targets in osteocytes under fluid shear stress (FSS) stimulation was tested using qRT-PCR to explore mechanical sensitivity and bone health mechanisms. Our findings revealed five metabolites affecting total body BMD and osteopenia, with biliverdin emerging as a potential protective factor against osteopenia (OR = 0.93, 95 %CI = 0.88-0.98, = 0.009). Additionally, three genes-LRRC14, SLC22A16, and TNFRSF1A-were identified as potential therapeutic targets for osteopenia. Notably, LRRC14 and TNFRSF1A are also associated with other musculoskeletal diseases. In vitro experiments showed that FSS significantly increased LRRC14 expression in osteocytes, suggesting its potential as a mechanosensitive factor. This study identifies candidate blood metabolites and mechanomedicine targets for osteopenia, offering a scientific basis for new diagnostic and treatment strategies and deepening our understanding of bone mechanics response characteristics. - Source: PubMed
Publication date: 2025/06/09
Liu RuobingHuang YaruJiang MaogangXu FeiPei QilinMa JiajunLi YouruShen SiqiZhang BoGuo XiangyangCai JingWang Wenwen - Male infertility is an intricate multifactorial disease involving the interplay between genetic and environmental factors. Genetic anomalies account for more than 15% of all male infertility cases; however, diagnosing them exhibits enormous challenges due to variable symptomatic presentations and limited knowledge of gene functions. Therefore, a thorough investigation into gene regulatory networks underlying male reproduction is demanded to improve patient counseling and infertility treatment. - Source: PubMed
Publication date: 2025/06/26
Chang Hsin-YiLu YonggangYamamoto KaitoSun JiangShimada KeisukeHiradate YukiFujihara YoshitakaIkawa Masahito